Home
ZVSA
ZVSA News

Latest ZyVersa Therapeutics Inc. (ZVSA) News on April 28, 2025

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status

GlobeNewswire

4 days ago

ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status

Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?

Insider Monkey

18 days ago

Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)

GlobeNewswire

20 days ago

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

a month ago

ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

GlobeNewswire

a month ago

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model

GlobeNewswire

2 months ago

ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

GlobeNewswire

2 months ago

ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes

GlobeNewswire

2 months ago

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco

GlobeNewswire

4 months ago

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco

Zacks Small Cap Research

5 months ago

OTC Markets Hosts Virtual Investor Presentation with Stephen Glover, CEO of ZyVersa Therapeutics, Inc., with Brad Sorensen, Senior Analyst at Zacks SCR

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

GlobeNewswire

5 months ago

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

GlobeNewswire

5 months ago

Life Sciences Investor Forum: Presentations Now Available for Online Viewing

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

Life Sciences Investor Forum Agenda Announced for November 14th

GlobeNewswire

6 months ago

Life Sciences Investor Forum Agenda Announced for November 14th

MT Newswires

6 months ago

ZyVersa Says Data Show Inflammasome Inhibition May Slow Obesity-Linked Diabetes; Shares Jump

MT Newswires

6 months ago

Top Premarket Gainers

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

GlobeNewswire

6 months ago

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

GlobeNewswire

6 months ago

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

GlobeNewswire

6 months ago

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

GlobeNewswire

6 months ago

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

GlobeNewswire

6 months ago

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

GlobeNewswire

7 months ago

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

GlobeNewswire

9 months ago

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

GlobeNewswire

9 months ago

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

GlobeNewswire

9 months ago

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

GlobeNewswire

9 months ago

ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

GlobeNewswire

9 months ago

ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024

GlobeNewswire

10 months ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

GlobeNewswire

a year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease

GlobeNewswire

a year ago

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

GlobeNewswire

a year ago

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire

a year ago

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

GlobeNewswire

a year ago

ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024

GlobeNewswire

a year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

GlobeNewswire

a year ago

ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

GlobeNewswire

a year ago

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

GlobeNewswire

a year ago

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

GlobeNewswire

a year ago

ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

GlobeNewswire

a year ago

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones

IF Bancorp (NASDAQ:IROQ) investors are sitting on a loss of 10% if they invested five years ago

Simply Wall St.

a year ago

IF Bancorp (NASDAQ:IROQ) investors are sitting on a loss of 10% if they invested five years ago

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

GlobeNewswire

a year ago

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

GlobeNewswire

a year ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

ClearOne to Showcase Conference and Collaboration Solutions for Every Size of Meeting Space at ISE 2024

Business Wire

a year ago

ClearOne to Showcase Conference and Collaboration Solutions for Every Size of Meeting Space at ISE 2024

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease

GlobeNewswire

a year ago

ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

GlobeNewswire

a year ago

PetVivo Recieves Notice of Allowance from United States Patent and Trademark Office for Key Patent Application

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

GlobeNewswire

a year ago

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

GlobeNewswire

a year ago

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Ikena Oncology to lay off 35% of staff

BioPharma Dive

a year ago

Ikena Oncology to lay off 35% of staff

Datasea Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

PR Newswire

a year ago

Datasea Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?

Benzinga

a year ago

Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?

Signing Day Sports President Richard Symington Interviewed on “The Big Biz Show”

GlobeNewswire

a year ago

Signing Day Sports President Richard Symington Interviewed on “The Big Biz Show”

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

ACCESSWIRE

a year ago

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

China Liberal Education Holdings Limited Announces Share Consolidation

PR Newswire

a year ago

China Liberal Education Holdings Limited Announces Share Consolidation

Cohen & Company Capital Markets Highlights Strong 2023

PR Newswire

a year ago

Cohen & Company Capital Markets Highlights Strong 2023

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis

GlobeNewswire

a year ago

ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis

BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

GlobeNewswire

a year ago

BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

GlobeNewswire

a year ago

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

Business Wire

a year ago

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access

GlobeNewswire

a year ago

ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access

HNR Acquisition Corp Announces 2024 Operational Plan - Increase in Production Expected in 2024; Cost Control and Optimizing Production to Increase Revenues and Earnings

ACCESSWIRE

a year ago

HNR Acquisition Corp Announces 2024 Operational Plan - Increase in Production Expected in 2024; Cost Control and Optimizing Production to Increase Revenues and Earnings

ACCESSWIRE

a year ago

iAccess Alpha Tax Loss Recovery Summit 2024 - Buyside Best Ideas January 9th-10th 2024

ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

GlobeNewswire

a year ago

ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024

GlobeNewswire

a year ago

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024

Yunji Announces Appointment of New Independent Director

PR Newswire

a year ago

Yunji Announces Appointment of New Independent Director

Paragon Reminds OPT Shareholders to ONLY Vote Blue Proxy and Send Message to OPT Board that Change is Needed to Avoid Continued Shareholder Losses

ACCESSWIRE

a year ago

Paragon Reminds OPT Shareholders to ONLY Vote Blue Proxy and Send Message to OPT Board that Change is Needed to Avoid Continued Shareholder Losses

Pioneer Power Announces e-Bloc and Related Product Orders in Excess of $10 Million

Business Wire

a year ago

Pioneer Power Announces e-Bloc and Related Product Orders in Excess of $10 Million

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC

ACCESSWIRE

a year ago

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC

cbdMD Reduces Year over Year Net Loss from Operations by $55.8 Million

Newsfile

a year ago

cbdMD Reduces Year over Year Net Loss from Operations by $55.8 Million

Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals

Zacks

a year ago

Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals

Gaucho Holdings Announces Fireside Chat with CNBC and Fox Business Network Market Analyst Kenny Polcari

ACCESSWIRE

a year ago

Gaucho Holdings Announces Fireside Chat with CNBC and Fox Business Network Market Analyst Kenny Polcari

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”

GlobeNewswire

a year ago

ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”

Dragonfly Energy Partners with Connexa, Fueling Industrial Solar Power System Applications

GlobeNewswire

a year ago

Dragonfly Energy Partners with Connexa, Fueling Industrial Solar Power System Applications

Nuvve Releases Letter to Stockholders

PR Newswire

a year ago

Nuvve Releases Letter to Stockholders

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

GlobeNewswire

a year ago

Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor

Chanson International Holding's (NASDAQ:CHSN) CEO Gang Li is the most upbeat insider, and their holdings increased by 238% last week

Simply Wall St.

a year ago

Chanson International Holding's (NASDAQ:CHSN) CEO Gang Li is the most upbeat insider, and their holdings increased by 238% last week

Usio Welcomes Payments Veteran Mr. Jerry Uffner as Senior Vice President of Card Issuing Sales

Business Wire

a year ago

Usio Welcomes Payments Veteran Mr. Jerry Uffner as Senior Vice President of Card Issuing Sales

EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody

Benzinga

a year ago

EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody

La Rosa Implements Final Offer to Deliver Transparency in Real Estate Transactions

GlobeNewswire

a year ago

La Rosa Implements Final Offer to Deliver Transparency in Real Estate Transactions

Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now

GlobeNewswire

a year ago

Carbon Revolution plc Awarded Program by Premium Brand of Major German Automaker

Globus Maritime (NASDAQ:GLBS) shareholders notch a 109% return over 1 year, yet earnings have been shrinking

Simply Wall St.

a year ago

Globus Maritime (NASDAQ:GLBS) shareholders notch a 109% return over 1 year, yet earnings have been shrinking

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

GlobeNewswire

a year ago

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation

Simply Wall St.

a year ago

Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation

Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application

ACCESSWIRE

a year ago

Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application

Valens Semiconductor's New USB3.2 Extension Solution Named as CES 2024 Innovation Awards Honoree

PR Newswire

a year ago

Valens Semiconductor's New USB3.2 Extension Solution Named as CES 2024 Innovation Awards Honoree

Associated Press Finance

a year ago

Gulf Resources: Q3 Earnings Snapshot

Gulf Resources Reports Unaudited Financial Results for Three and Nine Months Ended September 30,2023

GlobeNewswire

a year ago

Gulf Resources Reports Unaudited Financial Results for Three and Nine Months Ended September 30,2023

MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q

GlobeNewswire

a year ago

MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q

PR Newswire

a year ago

RICHMOND MUTUAL BANCORPORATION, INC. ANNOUNCES QUARTERLY DIVIDEND

Investors Holding Back On CaliberCos Inc. (NASDAQ:CWD)

Simply Wall St.

a year ago

Investors Holding Back On CaliberCos Inc. (NASDAQ:CWD)

Associated Press Finance

a year ago

Phoenix New Media: Q3 Earnings Snapshot

GlobeNewswire

a year ago

Interactive Strength Inc. d/b/a FORME Reports Third Quarter 2023 Results

Sonder Holdings Inc. Announces Third Quarter 2023 Financial Results

GlobeNewswire

a year ago

Sonder Holdings Inc. Announces Third Quarter 2023 Financial Results

Strawberry Fields REIT Inc. Announces Share Repurchase Program

ACCESSWIRE

a year ago

Strawberry Fields REIT Inc. Announces Share Repurchase Program

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

GlobeNewswire

a year ago

BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire

a year ago

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

ENGlobal Announces Third Quarter 2023 Financial and Operating Results

ACCESSWIRE

a year ago

ENGlobal Announces Third Quarter 2023 Financial and Operating Results

CHARLES & COLVARD REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS

PR Newswire

a year ago

CHARLES & COLVARD REPORTS FIRST QUARTER FISCAL YEAR 2024 FINANCIAL RESULTS

Adamas One Corp. Announces Formation of Adamas Technologies

PR Newswire

a year ago

Adamas One Corp. Announces Formation of Adamas Technologies

Share on Social Networks: